Reported Earlier, Arrowhead Plans $500M Convertible Senior Notes Due 2032 And $200M Common Stock Offerings To Fund R&D And Potential Commercial Launch Preparation

Arrowhead intends to use a portion of the net proceeds from the note offering to fund the cost of entering into the capped call transactions described below. Arrowhead intends to use the remainder of the net proceeds from the note offering, together with the net proceeds from the common stock offering, for general corporate purposes, including working capital, capital expenditures, research and development expenditures, clinical trial expenditures, commercialization activity expenditures and preparation for potential commercial launches of late stage products, including associated supply chain activities. A portion of the net proceeds may also be used to prepay the loans under Arrowhead's credit facility with Sixth Street Lending Partners. I